Stockscreener 앱 받기
269.89
0.76%
2.04
시간 외 거래:
270.16
0.27
+0.10%
전일 마감가:
$267.85
열려 있는:
$266.42
하루 거래량:
203.96K
Relative Volume:
0.86
시가총액:
$7.28B
수익:
$2.58B
순이익/손실:
$-778.69M
주가수익비율:
-9.8752
EPS:
-27.33
순현금흐름:
$223.75M
1주 성능:
-5.20%
1개월 성능:
-8.10%
6개월 성능:
-5.60%
1년 성능:
+7.52%
1일 변동 폭
$265.57
$270.77
1주일 범위
$264.92
$288.81
52주 변동 폭
$211.43
$343.12
Bio Rad Laboratories Inc Stock (BIO) Company Profile
명칭
Bio Rad Laboratories Inc
전화
(510) 724-7000
주소
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
269.89 | 7.23B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
110.25 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
345.78 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
88.97 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.63 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.09 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-08-28 | 개시 | Wells Fargo | Equal Weight |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-04-03 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-12-07 | 개시 | UBS | Buy |
| 2023-06-16 | 개시 | Wells Fargo | Overweight |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-01-28 | 재확인 | Citigroup | Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2018-10-17 | 개시 | Goldman | Buy |
| 2018-09-20 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-02-16 | 다운그레이드 | CL King | Buy → Neutral |
| 2017-07-13 | 개시 | Wells Fargo | Outperform |
| 2017-06-28 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Hold |
| 2016-10-13 | 개시 | CL King | Buy |
| 2015-05-06 | 재확인 | Jefferies | Buy |
| 2009-12-18 | 개시 | Maxim Group | Buy |
| 2009-11-06 | 개시 | Jefferies & Co | Buy |
| 2009-07-17 | 개시 | Soleil | Buy |
| 2007-09-26 | 개시 | Banc of America Sec | Buy |
| 2007-02-23 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
모두보기
Bio Rad Laboratories Inc 주식(BIO)의 최신 뉴스
Molecular Diagnostics Market Outlook: Set to Grow at 10%+ CAGR Through 2031 as Precision Medicine and Genetic Testing Advance, Says Mordor Intelligence - GlobeNewswire Inc.
Assessing Whether Bio-Rad Laboratories (BIO) Looks Undervalued After Recent Share Price Softness - Yahoo Finance
Bio-Rad Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Chipmakers Recap: Is Bio Rad Laboratories Inc stock forming a triangle patternJuly 2025 Intraday Action & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Dimensional Fund Advisors LP Purchases 63,370 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Published on: 2026-03-07 12:19:08 - baoquankhu1.vn
TD Asset Management Inc Purchases 7,386 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories, Inc. $BIO Shares Bought by GW&K Investment Management LLC - MarketBeat
Portfolio Shifts: Will Bio Rad Laboratories Inc outperform its industry peersQuarterly Risk Review & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Teachers Retirement System of The State of Kentucky Has $10.22 Million Stake in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Analysts Issue Forecasts for BIO FY2028 Earnings - MarketBeat
Medical Dry Fluorescence Immunoassay Analyzer Market Is Going - openPR.com
Automatic Blood Group Diagnostic Instrument Market Is Going - openPR.com
Assessing Bio-Rad (BIO) Valuation After Mixed Share Price Performance And Recurring Revenue Shift - simplywall.st
Roubaix Capital LLC Buys Shares of 8,112 Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Zacks Research Has Bearish Estimate for BIO Q1 Earnings - MarketBeat
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a 16.36% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Digital PCR Market to Reach US$ 14.37 Billion by 2033 at 9.8% CAGR; - openPR.com
Artisan Partners Limited Partnership Has $24.22 Million Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Westfield Capital Management Co. LP Increases Stock Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Is It Time To Reconsider Bio-Rad Laboratories (BIO) After Its Prolonged Share Price Slump - Sahm
Bio-Rad Laboratories, Inc. $BIO Shares Sold by Vanguard Group Inc. - MarketBeat
A Look At Bio Rad Laboratories (BIO) Valuation After Recent Share Price Weakness - simplywall.st
(BIO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Molecular Biology Analyzers Market Set to Boom by 2033: - openPR.com
Microfluidics Research Report 2026-2035: A $20.73 Billion - GlobeNewswire
Microfluidics Research Report 2026-2035: A $20.73 Billion Market by 2030 with Thermo Fisher Scientific, PerkinElmer, Dolomite, Agilent Technologies, Bio-Rad Laboratories, and Fluidigm Leading - Yahoo Finance
Bio-Rad Laboratories (NYSE:BIO.B) Shares Pass Below 200-Day Moving AverageTime to Sell? - MarketBeat
Weekly Earnings: What is the long term forecast for Bio Rad Laboratories Inc stockJuly 2025 Reactions & High Win Rate Trade Alerts - baoquankhu1.vn
International Markets and Bio-Rad (BIO): A Deep Dive for Investors - Yahoo Finance
Bio-Rad Laboratories, Inc. $BIO Shares Sold by ICICI Prudential Asset Management Co Ltd - MarketBeat
Blood Grouping Reagents Market Top Key Players -Grifols, Roche, - openPR.com
Hemocytometer Market Is Going to Boom Rapidly With Top Key - openPR.com
CenterBook Partners LP Has $2.56 Million Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
4 Undervalued Life Sciences Tools & Services Stocks for Thursday, February 19 - AAII
Bio-Rad Updates Investors on Sartorius Strategic Investment Metrics - TipRanks
Sartorius 2025 results summarized in Bio-Rad (NYSE: BIO) update - Stock Titan
Bio-Rad Laboratories, Inc. (BIO) achieves modest revenue growth and robust free cash flow growth - MSN
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth - Finviz
Risk Hedge: Is RBOT still a buy after recent gains2025 Institutional Moves & Stock Timing and Entry Methods - baoquankhu1.vn
Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down - Yahoo Finance
Protein Engineering Market to Grow at 15.6% CAGR from 2025 - openPR.com
Bio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Protein Engineering Market Is Going to Boom Rapidly With Top Key - openPR.com
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
United States Molecular Quality Controls Market to Reach CAGR - openPR.com
Dematic Automation Solution drives precision and productivity for Bio-Rad Singapore - mhdsupplychain.com.au
MSN Money - MSN
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Unveiling a 27.85% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Is It Time To Reassess Bio-Rad Laboratories (BIO) After Multi Year Share Price Weakness - Yahoo Finance
Bio Rad Laboratories Inc (BIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.21%
0.24%
자본화:
|
볼륨(24시간):